NDA 219835 · Rigel Pharms
Veppanu
Vepdegestrant · Oral
NovelCDER novel approval, May 1, 2026: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 1, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
2 Phase 3, 3 recruiting
FAERS reports
7
7 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 12, 2026.
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. ( 1 )
Therapeutic areas: Oncology · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- VEPPANU · VEPDEGESTRANT 200MG · TABLET, ORAL · Prescription
- VEPPANU · VEPDEGESTRANT 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vepdegestrant" as an intervention, any sponsor and status, largest first.
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05654623 · 624 participants · Start Mar 3, 2023 · Primary completion Jan 31, 2025
Drug: ARV-471; Fulvestrant · For: Advanced Breast Cancer
Sites: Encinitas, California; Fountain Valley, California; Fresno, California · 312 sites in all
PfizerPfizer (PFE)
NCT04606446 · 320 participants (planned) · Start Nov 16, 2020 · Primary completion Aug 27, 2029
Drug: PF-07248144; Fulvestrant and 4 more · For: Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 43 sites in all
Arvinas Estrogen Receptor, Inc.Industry
NCT04072952 · 219 participants · Start Sep 22, 2019 · Primary completion Sep 13, 2024
Drug: Vepdegestrant; Vepdegestrant and 1 more · For: Breast Cancer
Sites: Palo Alto, California; San Francisco, California; Santa Monica, California · 16 sites in all
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryPivotal-lookingCompleted
Arvinas Inc.Industry
NCT05549505 · 152 participants · Start Feb 15, 2023 · Primary completion Jul 13, 2024
Drug: ARV-471; Anastrozole · For: Breast Cancer
Sites: Springdale, Arkansas; Los Angeles, California; Torrance, California · 49 sites in all
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruiting
PfizerPfizer (PFE)
NCT06206837 · 71 participants · Start Feb 19, 2024 · Primary completion Sep 5, 2025
Drug: vepdegestrant; PF-07220060 · For: Breast Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 58 sites in all
RayzeBio, Inc.Industry
NCT06590857 · 64 participants (planned) · Start Jul 19, 2024 · Primary completion Oct 2028
Drug: RYZ101; Standard of Care Endocrine Therapy · For: Metastatic Breast Cancer; HER2-negative Breast Cancer; ER+ Breast Cancer and 7 more
Sites: Phoenix, Arizona; Irvine, California; San Diego, California · 32 sites in all
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05909397 · 59 participants · Start Aug 9, 2023 · Primary completion Dec 30, 2026
Drug: Vepdegestrant (ARV-471/PF-07850327); Letrozole · For: Breast Cancer
Sites: Plantation, Florida; Norfolk, Virginia; Adelaide, Australia · 29 sites in all
PfizerPfizer (PFE)
NCT06347861 · 52 participants · Start Apr 2, 2024 · Primary completion Jul 22, 2024
Drug: single dose of vepdegestrant as tablet formulation (Treatment A); single dose of vepdegestrant as tablet formulation (Treatment B) and 1 more · For: Healthy
Sites: Saint Paul, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia2
- blood pressure decreased1
- blood sodium decreased1
- breast cancer1
- death1
- fall1
- localised oedema1
- malignant neoplasm progression1
- product dose omission issue1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Campone M, De Laurentiis M, Jhaveri K, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ߙadvanced breast cancer: a phase 1 study.
Iwata H, Naito Y, Hattori M, et al. · Int J Clin Oncol 2025 · Clinical Trial, Phase I, Multicenter Study
- Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader.
Yang DZ, Masters JC, Wang H, et al. · J Clin Pharmacol 2026 · Clinical Trial, Phase I, Randomized Controlled Trial
- Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants.
Yang DZ, Zhou L, Winton JA, et al. · Br J Clin Pharmacol 2025 · Clinical Trial, Phase I
- The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants.
Tran L, Winton JA, Matschke KT, et al. · Clin Ther 2026 · Clinical Trial, Phase I
- A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants.
Yang DZ, Matschke KT, Winton JA, et al. · Eur J Drug Metab Pharmacokinet 2026 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Rigel Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.